Out of the 1.3 million individuals between the ages of 50-79 who are diagnosed with cancer, only 15% of those cases will be caught early. Aspen Institute and USC Schaeffer Center partnered for an expert discussion on early detection technologies.
The publication of the final rebate rule is an important milestone in this administration’s drug pricing journey. However, many challenges remain.
The percentage of total Medicare Part D drug spending offset by rebates on branded drugs increased from 11% in 2010 to 25% in 2018.
Part 1 of a panel series on health care price regulation honoring Uwe E. Reinhardt (1937-2017)
This paper revisits expert predictions for future advances in Alzheimer’s disease (AD) made in 2001 and projects future breakthroughs over the next 20 years.
What changes should be made now to the U.S. healthcare system to make it better when things return to a new normal, and, in the event of future pandemics.
The so-called “rebate rule” was reported dead in 2019. Here’s why that may not be entirely true.
Two years after launch, biosimilars for rheumatoid arthritis and other lifelong conditions captured little market share.
Schaeffer Center research indicates public investment into biomedical innovation yields substantial economic and social return in California.
Our analysis shows the measure resulted in over 56,000 jobs created and added approximately $10 billion to the state’s economy.